Helix Miss(30,500 +2.69%)Announced on the 20th that it will participate in the’Advanced Therapy Showcase’ held by the Japanese Life Science Association’Life Science Innovation Network Japan’ (LINK-J).
Representative Kim Sun-young attends as a presenter. Engensys (VM202) will announce the latest clinical development status and the company’s business strategy online from 1:30 pm on the 21st.
This event will be held for the first time this year as a conference in the field of advanced biotherapy such as cell and gene therapy and regenerative medicine. This event is held in a non-face-to-face format, and a total of 14 global pharmaceutical and bio companies participate.
Helix Miss introduces the unique technology and clinical progress of Engensys, a gene therapy drug, at this event. Engensys is a plasmid DNA gene therapy product that expresses hepatocyte growth factor (HGF) protein. It explains that it does not simply manage pain, but targets the root cause of neuropathy through angiogenesis and nerve regeneration effects.
The U.S. Food and Drug Administration (FDA) designated Engensys as an advanced regenerative medicine treatment (RMAT) in 2018. Currently, clinical trials are underway for diabetic neuropathy (DPN), amyotrophic lateral sclerosis (ALS), and Charcomaritus (CMT).
CEO Kim Sun-young said, “We want to share the current state of clinical development of Engensys and introduce its outstanding safety and high effectiveness as a gene therapy product.” I expect it to be,” he said.
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution